Last reviewed · How we verify
AD 337
AD 337 is a small molecule targeting the S1P1 receptor.
AD 337 is a small molecule targeting the S1P1 receptor. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | AD 337 |
|---|---|
| Sponsor | Sosei |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
S1P1 is a sphingosine-1-phosphate receptor involved in lymphocyte trafficking and immune response. By targeting this receptor, AD 337 aims to modulate immune cell activity and potentially treat autoimmune diseases.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. (PHASE2)
- A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD 337 CI brief — competitive landscape report
- AD 337 updates RSS · CI watch RSS
- Sosei portfolio CI